Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
| Class:Id | LiteratureReference:2399826 |
|---|
| _displayName | Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity |
|---|
| _timestamp | 2012-07-12 20:09:14 |
|---|
| author | [Person:2399857] Maira, Sauveur-Michel
[Person:2399876] Stauffer, Frédéric
[Person:2399809] Brueggen, Josef
[Person:2399770] Furet, Pascal
[Person:2399796] Schnell, Christian
[Person:2399745] Fritsch, Christine
[Person:2399775] Brachmann, Saskia
[Person:2399838] Chène, Patrick
[Person:2399769] De Pover, Alain
[Person:2399884] Schoemaker, Kevin
[Person:1678881] Fabbro, D
[Person:2399734] Gabriel, Daniela
[Person:2399814] Simonen, Marjo
[Person:2399862] Murphy, Leon
[Person:2399742] Finan, Peter
[Person:2399877] Sellers, William
[Person:2399763] García-Echeverría, Carlos |
|---|
| created | [InstanceEdit:2399727] Orlic-Milacic, M, 2012-07-12 |
|---|
| journal | Mol. Cancer Ther. |
|---|
| pages | 1851-63 |
|---|
| pubMedIdentifier | 18606717 |
|---|
| title | Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity |
|---|
| volume | 7 |
|---|
| year | 2008 |
|---|
| (literatureReference) | [Reaction:2400009] PI3K inhibitors block PI3K catalytic activity [Homo sapiens]
[Reaction:9732513] PI3K inhibitors bind to Activator:PI3K [Homo sapiens]
[ChemicalDrug:2399744] BEZ235 [cytosol]
[CandidateSet:2399811] PI3K/mutant PI3K inhibitors [cytosol]
[CandidateSet:9732428] PI3K inhibitors [cytosol]
[Summation:2404213] A variety of inhibitors capable of blocking the phosphoinosi...
[Summation:9732467] A variety of inhibitors capable of blocking the phosphoinosi... |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity (2399826)
